Though pathology in end-stage renal disease (ESRD) patients with high total homocysteine (tHcy) can be established, the research findings with vascular access thrombosis (VAT) and tHcy are equivocal. Investigators have found significantly higher homocysteine levels in patients with recurrent VAT compared with one or less episodes of thrombosis. Initial prospective evidence supports an independent association between tHcy levels and access thrombosis.
